Jin and Juice Investments

Who knew investing could be so much fun =D

XOMA’s Strategic Agenda – Words from CEO Mr. Engle

with 4 comments

XOMA

XOMA

Recently, the Wall Street Transript released their Biotechnology report which provides a unique and informative insight into the future of a select few public companies.  Below is a brief interview with the CEO of XOMA, Mr. Steve Engle on the current events taking place at XOMA and his strategic agenda for the next few years.

“TWST Question: Please begin with a brief historical sketch of the company and a picture of the things you are doing at the present time.

Mr. Engle CEO of XOMA Response: We are a recognized leader in the discovery and development of therapeutic antibodies. Our lead product, XOMA 052, is a potentially revolutionary treatment for the inflammatory cause of many major diseases including Type II diabetes, cardiovascular disease and autoimmune diseases. In addition, XOMA receives revenues from: the licensing of its antibody technologies to over 50 companies; product royalties (LUCENTIS and CIMZIA); development collaborations with Takeda, Novartis and Schering-Plough; and biodefense contracts. Based in Berkeley, California, XOMA has 200 employees.Our lead product candidate, XOMA 052, is a proprietary antibody that regulates production of the cytokine called interleukin-1 or IL-1, which is the master cytokine in activating the inflammatory cascade. We recently received a US patent for XOMA 052, providing an important acknowledgement that it has properties that differentiate it from other agents that target IL-1. We recently completed enrollment in Phase I studies of XOMA 052 in Type II diabetes and plan to announce top-line results from the US trial in July. The trials evaluated a wide range of XOMA 052 doses, single and multiple dose regimens, and intravenous and subcutaneous routes of administration. Interim results presented last fall from the single dose IV trials demonstrated that XOMA 052 is well tolerated across all doses. Further, XOMA 052 showed evidence of biological activity, including reduced levels of glycosylated hemoglobin, increased insulin production and reduced levels of C-reactive protein, or CRP, compared to placebo. CRP is a well-established marker for the systemic inflammation associated with cardiovascular disease, one of the largest pharmaceutical markets. For this reason, we have begun to evaluate XOMA 052 for its potential cardiovascular benefits in addition to considering it for development in diabetes and autoimmune diseases. In addition to XOMA 052 and the other products in our proprietary pipeline, we have a business focused on collaborations with other companies using our broad antibody technologies, a business focused on biodefense funded by the US government, and a royalty-based business based on our pioneering position in developing antibodies for therapeutic uses. We currently receive royalties on sales of LUCENTIS from Genentech and CIMZIA from UCB.

TWST Question: Would you sketch out your strategic agenda for the next two to three years?

Mr. Engle CEO of XOMA Response: We are very focused on advancing the development of XOMA 052 for diabetes and cardiovascular disease because it is a revolutionary approach and has the greatest single potential for maximizing the return to shareholders. Discussions toward a corporate partnership for XOMA 052 are underway and we plan to finalize this partnership by year-end. We plan to advance XOMA 052 for other indications and continue bringing forward the other proprietary compounds we have in pre-clinical development. With the advancement of XOMA 052, establishment of a corporate partnership, advancement of our pre-clinical pipeline and our other businesses, we believe we have multiple opportunities to significantly grow shareholder value.”

www.twst.com

Therapeutic Antibodies Potential to Revolutionalize Treatment of Autoimmune Diseases

�Analysts Recommendations

current 1 Month Ago 3 Months Ago
BUY 3 5 5
OVERWEIGHT 0 0 0
HOLD 1 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN OVERWEIGHT BUY BUY

Mean Recomendation Conversion Table
1.00 thru 1.24 = Buy
1.25 thru 1.74 = Overweight
1.75 thru 2.24 = Hold
2.25 thru 2.74 = Underweight
2.75 thru 3.00 = Sell
Copyright © 2006 FactSet JCF S.A.S. All rights reserved.

-Marketwatch.com

Advertisements

Written by jinandjuice2009

June 1, 2009 at 1:56 PM

4 Responses

Subscribe to comments with RSS.

  1. Engle is an idiot
    sorry

    pinebarknuggets

    June 5, 2009 at 12:13 PM

    • but xoma is good pick

      pinebarknuggets

      June 5, 2009 at 12:14 PM

    • Haha. Don’t let him fool you.

      jinandjuice2009

      June 6, 2009 at 5:12 PM

  2. I am going to make some serious bank on ZOMA, loading up at .80 while everyone is sleeping.

    Michael

    October 13, 2009 at 8:43 AM


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: